Upcoming Events.


September 14th 2020 - September 16th 2020

Immutep will participate to the virtual event format.

September 18th 2020 - September 22nd 2020

ESMO 2020 Congress

Immutep will participate to the virtual ESMO 2020 conference.

October 26th 2020 - October 29th 2020

Delivered Digitally - European Standard Time

Immutep will participate to the virtual Bio-Europe 2020 conference.

November 2nd 2020 - November 4th 2020
November 9th 2020 - November 14th 2020

Reimagined as a fully virtual experience

Immutep will participate to the virtual SITC 2020 conference.

January 11th 2021 - January 14th 2021

39th Annual J.P. Morgan Health Care Investor Conference

Past Events.


June 8th 2020 - June 12th 2020

Immutep will participate to the new virtual event format.

May 29th 2020 - May 31st 2020

Immutep will participate to the new virtual event format and will present:

“Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab”

&

"Open label, phase I study evaluating feasibility and safety of subcutaneous IMP 321
(a soluble LAG 3 protein, eftilagimod alpha) combined with avelumab in advanced stage
solid tumor entities results from stratum D of the INSIGHT platform trial"

Click here for the "TACTI-002" poster which will be presented at the virtual event - ASCO 2020

Click here for the "Insight" poster which will be presented at the virtual event - ASCO 2020

 

May 26th 2020 - May 27th 2020
May 7th 2020 - May 9th 2020
April 24th 2020 - April 29th 2020
March 26th 2020

Immutep AIPAC Data Global Webcast (ASX:IMM; NASDAQ:IMMP)

Immutep will present this AIPAC data in a global webcast, details are as follows:

Date & Time: Thursday, March 26th, 8am Australian Eastern Daylight Time / Wednesday, March 25th, 5pm US Eastern Daylight Time

Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link: http://public.viavid.com/index.php?id=138665

Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.

A replay of the webcast will also be available at www.immutep.com from the day after the event.

Click here for AIPAC Global Webcast Slides

February 26th 2020

Immutep Clinical Results Global Webcast (ASX:IMM; NASDAQ:IMMP)

The Company will present the interim TACTI-002 data and provide a further update on its clinical programs in a global webcast. The details for the webcast are as follows:

Date & Time: Wednesday, February 26, 2020, 8:00 am Australian Eastern Daylight Time / Tuesday, February 25, 2020, 4:00 pm US Eastern Daylight Time

Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link:
https://fnn.webex.com/fnn/onstage/g.php?MTID=e11208a0ff7fcccaca4d5e4b8a14e988f

Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.

A replay of the webcast will also be available at www.immutep.com from the day after the event.

January 13th 2020 - January 16th 2020

38th Annual J.P. Morgan Health Care Investor Conference

November 11th 2019 - November 13th 2019

Venue: CCH - Congress Center Hamburg, Am Dammtor / Marseiller Str., 20355 Hamburg, Germany

https://www.das-neue-cch.de

November 6th 2019 - November 10th 2019

The company will have presentations at the conference and representatives will be attending.

Venue: Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA

https://www.nationalharbor.com/gaylord-national/

Click here for the "TACTI-002" poster which will be presented at the SITC 2019

October 31st 2019

AusBiotech Investment Events 2019

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.  

Venue: Melbourne Convention & Exhibition Centre, Melbourne VIC 3006, Australia

https://www.ausbiotechinvestment.com.au/event-details 

October 15th 2019 - October 17th 2019

      

Day 1 – Tuesday, 15th October/ 2.50 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology

Click here for full agenda

Venue: Basel Congress Centre, Basel, Switzerland

September 27th 2019 - October 1st 2019

Representatives of the company will be attending the conference.

Venue:

www.firabarcelona.com

Fira Gran Via, Barcelona
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat, Spain

May 15th 2019 - May 17th 2019

Conference Day 2: Friday 17th May 2019/ 11.25.a.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials

Click here for the Presentation at World Advanced Therapies & Regenerative Medicine Congress & Expo 2019

Venue: Business Design Centre, London, UK

May 14th 2019 - May 15th 2019

Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion.

Venue: The New York Academy of Sciences, New York, New York, USA

March 29th 2019 - April 3rd 2019
March 3rd 2019 - March 5th 2019

Day 2 – Tuesday 5th March/ 3.00 p.m.  

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients

click here for presentation

Venue:  Grand Hyatt, San Diego, USA

January 7th 2019 - January 10th 2019

37th Annual J.P. Morgan Health Care Investor Conference

Venue:    San Francisco, California, USA

November 27th 2018 - November 29th 2018

conference day 1/ 02.00 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTIve Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab

Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany

November 16th 2018
November 8th 2018

Marc Voigt, CEO of Immutep, will present a corporate overview and business update.

Venue: Macquarie Office -  Sydney, Australia

click here for agenda

November 7th 2018 - November 11th 2018

The company will have presentations at the conference and representatives will be attending.

Venue:    Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C., DC 20001, USA

October 30th 2018

day 2/ 2:55 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor
(Eftilagimod Alpha) with Pembrolizumab

click here for agenda / day 2

click here for presentation

Venue:   Basel Congress Center, Basel, Switzerland

October 30th 2018

Marc Voigt, CEO of Immutep, will present a corporate overview and business update.

Venue: Sofitel Melbourne on Collins, Melbourne VIC 3000, Australia

click here to view program of the event

October 24th 2018 - October 27th 2018

Dr. Victoria Atkinson (Principal Investigator TACTI-mel) speaks on the subject:

"Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma."

Venue: Manchester Central Convention Complex, Manchester, United Kingdom

October 19th 2018 - October 23rd 2018

Representatives of the company will be attending the conference.

Venue:   Messe Munich, Messegelände, 81823 Munich, Germany, www.messe-muenchen.de

October 2nd 2018

Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.immutep.com.

Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”

Download "Ladenburg 2018 HC Conference Immutep Presentation"

September 7th 2018

BioCentury 25th Annual NewsMakers - Biotech Industry Conference

Marc Voigt, CEO of Immutep, will present a corporate overview and business update with one-on-one meetings held throughout the day. 

Venue:  Millenium Broadway Hotel & Conference Center, NY, USA

Press release: click here

Download "Newsmaker Immutep Corporate Presentation"

Listen to the webcast “Immutep Newsmakers Presentation” from September 7th, 2018

 

June 20th 2018

 - the largest networking event for life sciences and healthcare industries in the German capital region -

Venue:    Ludwig Erhard Haus, Fasanenstraße 85, Berlin, Germany

June 1st 2018

Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018

June 1st 2018

Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018

May 24th 2018 - May 25th 2018

Frédéric Triebel speaks on the subject:

“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”

May 16th 2018 - May 18th 2018
April 18th 2018 - April 19th 2018

Venue:  bbc (Berlin Congress Center), Alexanderstr. 11, 10178, Berlin, Germany

April 14th 2018 - April 18th 2018
April 9th 2018 - April 10th 2018

Company presentation by Jay R. Campbell at 9.00am EDT on Monday, April 9th

Venue:  Essex House, New York, NY, USA

Finance News Network Interview, 12. Nov. 2018, Immutep Limited (ASX:IMM) Executive Director and CEO, Marc Voigt provides an update on the company's clinical trials, collaboration with large pharma and key milestones.

Your Money - Interview with Marc Voigt (CEO), 31.10.2018

Finance News Network - Interview with Marc Voigt (CEO), 06.09.18

FNN – Interview with Immutep

Sky Business News - Interview with Marc Voigt (CEO), 30.04.18

Interview with Frédéric Triebel and Marc Voigt

CNBC - Interview with Marc Voigt (CEO)

Sky Business News - Interview with Marc Voigt (CEO), 25.11.15

The Business - Interview with Lucy Turnbull

Sky Business News - Interview with Marc Voigt (CEO), 16.05.14